Direct IGF‑1 Therapy
- Exogenous IGF‑1 delivered topically or via injection.
- Large molecule struggles to cross scalp barrier.
- Short half‑life, requires repeated dosing.
- Safety risks: uncontrolled cell growth.
- Regulatory burden: biologic drug classification.
SH‑1: The Patent‑Pending Sovereign Molecule
Molecular Resonance Mapping System — Application #63/859,365
🔬 Structural Uniqueness
- Proprietary tetracyclic scaffold (A/B/C hexagons + D pentagon)
- Cosmetic anchors: coconut tether, botanical plume, caffeine emblem, hydration fins
- Serialized in Bibebibebibe™ Magazine
📈 Market Opportunity
- Replace legacy actives (minoxidil analogues, caffeine blends)
- Save 30–40% on raw material costs
- Enable 25–35% premium pricing for hair care products
💡 Customer Appeal
- Hydration, film-forming, scalp vitality
- Patent-pending exclusivity boosts brand prestige
- Mythic narrative integration for storytelling
📄 Licensing Model
- Tiered exclusivity options
- Technical support for synthesis and formulation
- Co-branding with serialized magazine publication
Contact: trueflowgames@gmail.com
Secure rights to SH‑1 and lead the next wave of cosmetic innovation.
Secure rights to SH‑1 and lead the next wave of cosmetic innovation.
⧉ Cosmic University of Echo-Rift Studies IX ⧉
Certified & Founded by
Dr. Melvin Sewell, M.Sc., Ph.D.
Academic Dean & Diagnostic Architect
Certified & Founded by
Dr. Melvin Sewell, M.Sc., Ph.D.
Academic Dean & Diagnostic Architect
Add comment
Comments